LH · Labcorp Holdings Inc
Price
Snapshot
50 fields · last close| Market Cap | $25.79B |
| P/E | 25.73 |
| Float | 80.56M |
| Beta | 0.89 |
| Volatility | 22.3% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 82.7 |
| Price | 318.03 |
| Change | +0.03% |
| Prev Close | 317.95 |
| Open | 326.05 |
| Day Low | 316.12 |
| Day High | 327.50 |
| Avg Vol | 1 |
| Avg $ Vol | $198.2M |
| 52W High | 341.80 |
| 52W Low | 244.52 |
| 52W Pos | 75.6% |
| From High | −6.95% |
| From Low | +30.06% |
| Max DD 1Y | −15.22% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +1.89% |
| SMA 50 | −0.75% |
| SMA 200 | +12.23% |
| RSI (14) | 53.1 |
| Vol 30D | 24.9% |
| Vol 90D | 23.8% |
| 1Y Range | 245–342 |
| Daily bars | 536 |
| Perf Week | +1.86% |
| Perf Month | −1.48% |
| Perf Quarter | +12.96% |
| Perf Half Y | +17.46% |
| Perf Year | +12.45% |
| Perf YTD | +26.37% |
| Prev Day | +0.03% |
| Clavix | A- |
| Debt / Eq | 0.72 |
| Curr Ratio | 1.42 |
| Int Cover | 6.2× |
| FCF Margin | 8.6% |
| Rev Growth | +7.2% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 6 / 49 |
What LH does
Labcorp Holdings Inc. provides laboratory services.
It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests.
It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations.
In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI‑enabled Test Selection, a generative AI‑enabled tool.
It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs.
The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics.
It also has a collaboration with Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer.
The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Clavix risk grade
regraded every trading dayLH grades A-, 82.7 of 100. Steadiest on Price Stability (68), most exposed on News Sentiment (50, mixed). 2 of the 4 weighted dimensions sit above the Health Care median. Ranks 6 of 49 in Health Care by Clavix score.
How rough the ride is
| LH | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.89 | 0.84 |
| Volatilityannualized | 22.3% | 20.9% |
| Max drawdown, past yearworst peak-to-trough fall | −15.2% | — |
| Typical daily movemedian absolute daily change | 0.89% | — |
| Days beyond ±3%of the last 252 sessions | 12 (5%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| LH | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.89 | 0.84 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 53% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| LH | |
|---|---|
| 1 week | +1.9% |
| 1 month | −1.5% |
| Year to date | +26.4% |
| 1 year | +12.4% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| LH | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 14 Sep |
| Average score0 most bearish, 100 most bullish | 54 |
| Bullish · bearisharticles above 60 · below 40 | 17 · 10 |
| Directionarticles whose tone is improving vs worsening | 17 ↑ 10 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| LH | |
|---|---|
| Revenue growthyear over year | +7.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openOPKO Health is selling select BioReference assets to Labcorp for $722 million, with a potential additional $150 million earnout (a payment made after the deal closes if the acquired business hits performance targets). The sale is intended to sharpen OPKO's biopharma focus and expand access to the 4Kscore Test, a prostate cancer risk assessment.
OPKO Health is selling select assets of its BioReference laboratory business to Labcorp for $722 million, with up to $150 million more possible if future performance targets are met. The deal lets OPKO focus on its drug-development business and gives Labcorp broader access to OPKO's 4Kscore prostate cancer test.
LabCorp (LH) is acquiring BioReference from OPKO Health, and the article presents AI-generated reviews of the deal from ChatGPT and Claude. The article body is truncated, so full details on deal terms, price, or strategic rationale are not available.
LabCorp's acquisition of Bioreference includes carve-outs related to the 4Kscore prostate cancer test. Medicare Part B sales of that test (billing code 81539) grew from $10.4M on 13,700 units in 2023 to $11.7M on 15,300 units in 2024, and $12.6M on 16,500 units in 2025. The article also references current PAMA (a Medicare pricing program) rate data for 2026 but the figures are cut off.
Labcorp announced a deal to acquire BioReference's laboratory assets for up to $872 million, saying the purchase will improve patient and provider access to its laboratory services. The article is brief and provides no further detail on financing, timing, or expected synergies.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| DGX | Quest Diagnostics Inc | A- | $25.94B | 24.42 | 0.56 | Compare |
| ALC | Alcon AG | B+ | $27.54B | 40.81 | 1.07 | Compare |
| STE | STERIS plc | A- | $21.71B | 26.97 | 0.88 | Compare |
| THC | Tenet Healthcare Corp | B | $21.52B | 9.60 | 1.22 | Compare |
| GH | Guardant Health Inc | C+ | $21.28B | — | 1.71 | Compare |
| GEHC | GE Healthcare Technologies Inc | B | $31.42B | 15.83 | 0.83 | Compare |
| DXCM | Dexcom Inc | B | $32.47B | 32.48 | 1.44 | Compare |
| RMD | Resmed Inc | B+ | $33.61B | 22.06 | 0.77 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.